홈 > 시장보고서 > 의약품 > 파이프라인 분석

시장보고서

상품코드

2075938

모르키오 증후군(MPS-IV) 치료제 시장 : 제품 유형별, 치료법별, 질환 유형별, 유통 채널별, 지역별

Global Morquio Syndrome (MPS-IV) Drug Market, By Product Type, By Treatment, By Disease Type, By Distribution Channel, By Geography

발행일: 2026년 04월 | 리서치사: 구분자

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,451,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 10,035,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,337,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 모르키오 증후군(MPS-IV) 치료제 시장은 2026년에 210만 달러 규모로 추정되며, 2033년까지 500만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 12.9%로 성장할 전망입니다.

보고서 범위		보고서 상세
기준 연도 :	2025년	시장 규모(2026년) :	210만 달러
과거 데이터 기간 :	2020-2024년	예측 기간 :	2026-2033년
예측 기간 CAGR(2026-2033년) :	12.90%	시장 규모 예측(2033년) :	500만 달러

무코다당증 IV형(MPS IV)은 당 분자의 긴 사슬을 분해하는 데 필요한 효소가 체내에서 결핍되거나 충분하지 않은 희귀질환입니다. 이러한 분자 사슬은 글리코사미노글리칸(구 명칭 : 뮤코다당류)이라고 불립니다. 이 질환은 케라탄황산 및 콘드로이틴황산의 분해를 담당하는 효소인 N-아세틸갈락토사민-6-설파타제(GALNS) 또는 β-갈락토시다아제의 결핍으로 인해 발생합니다. 이러한 당분이 세포, 조직, 장기에 축적되면 골격 형성 이상, 저신장, 관절 이상, 기도 폐쇄 등의 호흡기 문제, 심장 기형, 난청, 각막 혼탁 등을 유발할 가능성이 있습니다. MPS-IV에는 완치할 수 있는 치료법이 없으며, 치료 방법은 증상 관리에 국한됩니다. 그러나 효소 보충 요법(ERT)과 조혈모세포 이식(HSCT)은 증상 관리와 환자의 삶의 질 향상 측면에서 일정한 성과를 거두고 있습니다. MPS IV는 유전성 질환입니다. 즉, 보통은 가족을 통해 대대로 전해집니다. 부모 양쪽 모두 이 질환과 관련된 유전자의 기능 결손형을 가지고 있는 경우, 자녀 한 명당 이 질환이 발병할 확률은 25%(4명 중 1명)가 됩니다. 이를 상염색체 열성 유전이라고 합니다.

시장 역학 :

세계 모르키오 증후군(MPS-IV) 치료제 시장은 주로 이 희귀 유전 질환의 유병률 증가, 이용 가능한 치료 옵션에 대한 인식 제고, 그리고 새로운 작용기전을 가진 유망한 개발 중인 약물들에 의해 주도되고 있습니다. 그러나 질환의 희귀성으로 인한 치료비 상승과 재조합 효소 제조에 수반되는 문제점 등이 시장 성장을 저해하는 요인으로 작용하고 있습니다. 그렇긴 하지만, 치료법의 개선, 희귀질환에 대한 연구 자금 증가, 그리고 시장 독점권을 부여하는 희귀질환 치료제 지정은 이 시장의 주요 기업들에게 유망한 사업 기회를 제공합니다.

본 조사의 주요 특징 :

본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 세계 모르키오 증후군(MPS-IV) 치료제 시장의 주요 기업 프로파일을 소개했습니다. 본 조사에서 다룬 주요 기업으로는 BioMarin Pharmaceutical Inc., Takeda Pharmaceutical Company Limited., Pfizer Inc., Sanofi, Novo Nordisk A/S, Concert Pharmaceuticals, Inc., Alexion Pharmaceuticals Inc., Novartis AG, Amgen Inc., Sangamo Therapeutics 및 JCR Pharmaceuticals Co., Ltd가 포함됩니다.
본 보고서에서 얻을 수 있는 인사이트는 각 기업의 마케팅 담당자 및 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내리는 데 도움이 될 것입니다.
세계의 모르키오 증후군(MPS-IV) 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계의 모르키오 증후군(MPS-IV) 치료제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 2.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	12.90%	2033 Value Projection:	USD 5.0 Mn

Mucopolysaccharidosis type IV (MPS IV) is a rare disease in which the body is missing or does not have enough of an enzyme needed to break down long chains of sugar molecules. These chains of molecules are called glycosaminoglycans (formerly called mucopolysaccharides). It is caused by a deficiency in the enzymes N-acetylgalactosamine-6-sulfatase (GALNS) or beta-galactosidase which is responsible for breaking down keratan sulfate and chondroitin sulfate. The accumulation of these sugars in cells, tissues, and organs can lead to skeletal dysplasia, short stature, joint abnormalities, and respiratory issues like airway obstruction, heart defects, hearing loss, and corneal opacity. There is no cure for MPS-IV and the treatment options are limited to symptom management. However, enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) have shown some success in management of symptoms and improvement in quality of life for patients. MPS IV is an inherited disorder. This means, it is typically passed down through families. If both parents carry a nonworking copy of a gene that is related to this condition, each of their children has a 25% (1 in 4) chance of developing the disease. This is called an autosomal recessive trait.

Market Dynamics:

Global morquio syndrome (MPS-IV) drug market is primarily driven by the rising prevalence of this rare genetic disorder, growing awareness about available treatment options and strong pipeline drugs with novel mechanisms of action. However, high cost of therapy due to rarity of disease as well as challenges that are associated with production of recombinant enzymes are some of the factors restraining the market growth. Nonetheless, development of improved treatment modalities, increasing research funding for rare diseases and orphan drug designation providing market exclusivity offers lucrative opportunities for the key market players in this market.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global morquio syndrome (MPS-IV) drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include BioMarin Pharmaceutical Inc., Takeda Pharmaceutical Company Limited., Pfizer Inc., Sanofi, Novo Nordisk A/S, Concert Pharmaceuticals, Inc., Alexion Pharmaceuticals Inc., Novartis AG, Amgen Inc., Sangamo Therapeutics, and JCR Pharmaceuticals Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global morquio syndrome (MPS-IV) drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global morquio syndrome (MPS-IV) drug market

Detailed Segmentation:

Global Morquio Syndrome (MPS-IV) Drug Market, By Product Type (Revenue, USD Mn, 2021 - 2033)
Solid Dosage Form
- Tablets
- Capsules
Liquid Dosage Form
- Injectable
- Others
Global Morquio Syndrome (MPS-IV) Drug Market, By Treatment (Revenue, USD Mn, 2021 - 2033)
Enzyme Replacement Therapy
Hematopoietic Stem Cell Therapy
Gene Therapy
Others
Global Morquio Syndrome (MPS-IV) Drug Market, By Disease Type (Revenue, USD Mn, 2021 - 2033)
Morquio A
Morquio B
Global Morquio Syndrome (MPS-IV) Drug Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Regional Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Top Companies in the Global Morquio Syndrome (MPS-IV) Drug Market:
BioMarin Pharmaceutical Inc.
Takeda Pharmaceutical Company Limited.
Pfizer Inc.
Sanofi
Novo Nordisk A/S
Concert Pharmaceuticals, Inc.
Alexion Pharmaceuticals Inc.
Novartis AG
Amgen Inc.
Sangamo Therapeutics
JCR Pharmaceuticals Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Treatment
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing Launch of Awareness Campaigns
- Lack of skilled healthcare professionals
- Rising healthcare expenditure
Key Highlights
Regulatory Scenario
Recent Trends
PEST Analysis
PORTER's Analysis
Product Launches
Mergers, Acquisitions, and Collaborations

4. Global Morquio Syndrome (MPS-IV) Drug Market, By Product Type, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Solid Dosage Form
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  - Tablets
  - Capsules
Liquid Dosage Form
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
  - Injectable
  - Others

5. Global Morquio Syndrome (MPS-IV) Drug Market, By Treatment, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Hematopoietic Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

6. Global Morquio Syndrome (MPS-IV) Drug Market, By Disease Type, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Morquio A
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Morquio B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

7. Global Morquio Syndrome (MPS-IV) Drug Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

8. Global Morquio Syndrome (MPS-IV) Drug Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 -2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profile
- BioMarin Pharmaceutical Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Takeda Pharmaceutical Company Limited.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sanofi
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Novo Nordisk A/S
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Concert Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Alexion Pharmaceuticals Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sangamo Therapeutics
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- JCR Pharmaceuticals Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
Analyst Views

10. Section

References
Research Methodology
About us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격